Skip to main content

Advertisement

SpringerLink
Log in

Effects of atorvastatin and ezetimibe on endothelial function in dyslipidemic patients with chronic kidney disease

  • Original Article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Backgroud

Chronic kidney disease (CKD) is a staple risk factor not only for renal failure but also for cardiovascular diseases. In addition, because dyslipidemia facilitates atherosclerosis and renal dysfunction, antihyperlipidemic treatment is important to prevent cardiac and renal events in CKD patients.

Methods

We compared the effects of a statin and an intestinal cholesterol transporter inhibitor in 20 dyslipidemic patients with CKD presenting with proteinuria and/or glomerular filtration rate <60 mL/min/1.73 m2. Either 5–10 mg atorvastatin or 10 mg ezetimibe was given for 3 months each in a randomized crossover manner and the parameters of oxidative stress, inflammation and endothelial function were compared.

Results

Atorvastatin lowered serum low-density lipoprotein (LDL) cholesterol more prominently than ezetimibe (103 ± 38 vs 130 ± 45 mg/dL, p < 0.001), while serum γ-glutamyl transpeptidase was higher in atorvastatin than in ezetimibe (29 ± 16 vs 25 ± 11 U/L, p = 0.013). On the other hand, serum oxidized LDL and high-sensitivity C-reactive protein were lower in the atorvastatin treatment period than in the ezetimibe treatment period (109 ± 38 vs 146 ± 67 U/L, p = 0.002; 1.02 ± 1.46 vs 1.47 ± 1.77 µg/mL, p = 0.003). Although serum adiponectin was not significantly different between the two drugs, the reactive hyperemia index, an index of endothelial function, was higher in atorvastatin than in ezetimibe (1.94 ± 0.58 vs 1.60 ± 0.44, p = 0.023).

Conclusion

It is concluded that atorvastatin is more potent than ezetimibe in improving the serum lipid profile, reducing oxidative stress, suppressing inflammation and preserving endothelial function, while ezetimibe may be advantageous in reducing the hepatic lipid load.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14:2084–91.

    PubMed  CAS  Google Scholar 

  2. Mänttäri M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension. 1995;26:670–5.

    Article  PubMed  Google Scholar 

  3. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59:260–9.

    Article  PubMed  CAS  Google Scholar 

  4. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17:2006–16.

    Article  PubMed  CAS  Google Scholar 

  5. Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation. 2005;112:171–8.

    Article  PubMed  CAS  Google Scholar 

  6. Japanese Society of Nephrology. Evidence-based practice guideline for the treatment of CKD. Clin Exp Nephrol. 2009;13:537–66.

    Article  Google Scholar 

  7. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, et al. Japan Atherosclerosis Society (JAS) Committee for Epidemiology and Clinical Management of Atherosclerosis. Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb. 2007;14:155–8.

    Article  PubMed  CAS  Google Scholar 

  8. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.

    Article  PubMed  CAS  Google Scholar 

  9. Harris M, Davis W, Brown WV. Ezetimibe. Drugs Today. 2003;39:229–47.

    Article  PubMed  CAS  Google Scholar 

  10. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Enjoji M, Machida K, Kohjima M, Kato M, Kotoh K, Matsunaga K, et al. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. Lipids Health Dis. 2010;9:29.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Shiwa T, Kawanami Y, Yokoyama T, Moritani A, Hashimoto M, Gotoh T. The efficacy of ezetimibe on nonalcoholic fatty liver disease (NAFLD). Nihon Shokakibyo Gakkai Zasshi. 2011;108:1383–92.

    PubMed  Google Scholar 

  13. Ruan XZ, Varghese Z, Moorhead JF. An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol. 2009;5:713–21.

    Article  PubMed  CAS  Google Scholar 

  14. Shoji T, Abe T, Matsuo H, Egusa G, Yamasaki Y, Kashihara N, et al. Chronic kidney disease, dyslipidemia, and atherosclerosis. J Atheroscler Thromb. 2012;19:299–315.

    Article  PubMed  CAS  Google Scholar 

  15. Nakamura T, Sato E, Amaha M, Kawagoe Y, Maeda S, Inoue H, et al. Ezetimibe reduces urinary albumin excretion in hypercholesterolaemic type 2 diabetes patients with microalbuminuria. J Int Med Res. 2012;40:798–803.

    Article  PubMed  CAS  Google Scholar 

  16. Landray M, Baigent C, Leaper C, Adu D, Altmann P, Armitage J, et al. The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis. 2006;47:385–95.

    Article  PubMed  CAS  Google Scholar 

  17. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.

    Article  PubMed  CAS  Google Scholar 

  18. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157:251–62.

    Article  PubMed  Google Scholar 

  20. Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157:263–75.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Nakamura H, Mizuno K, Ohashi Y, Yoshida T, Hirao K, Uchida Y. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis. 2009;206:512–7.

    Article  PubMed  CAS  Google Scholar 

  22. Kietadisorn R, Juni RP, Moens AL. Tackling endothelial dysfunction by modulating NOS uncoupling: new insights into its pathogenesis and therapeutic possibilities. Am J Physiol Endocrinol Metab. 2012;302:E481–95.

    Article  PubMed  CAS  Google Scholar 

  23. Moody WE, Edwards NC, Madhani M, Chue CD, Steeds RP, Ferro CJ, et al. Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association? Atherosclerosis. 2012;223:86–94.

    Article  PubMed  CAS  Google Scholar 

  24. Satoh M. Endothelial dysfunction as an underlying pathophysiological condition of chronic kidney disease. Clin Exp Nephrol. 2012;16:518–21.

    Article  PubMed  Google Scholar 

  25. Fliser D. Perspectives in renal disease progression: the endothelium as a treatment target in chronic kidney disease. J Nephrol. 2010;23:369–76.

    PubMed  Google Scholar 

  26. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109(23 Suppl 1):III39–43.

    Google Scholar 

  27. Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis. 2009;203:325–30.

    Article  PubMed  CAS  Google Scholar 

  28. Olijhoek JK, Hajer GR, van der Graaf Y, Dallinga-Thie GM, Visseren FL. The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial. J Cardiovasc Pharmacol. 2008;52:145–50.

    Article  PubMed  CAS  Google Scholar 

  29. Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, Visseren FL. The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients. Atherosclerosis. 2009;202:216–24.

  30. Yunoki K, Nakamura K, Miyoshi T, Enko K, Kohno K, Morita H, et al. Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. Atherosclerosis. 2011;217:486–91.

    Article  PubMed  CAS  Google Scholar 

  31. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.

    Article  PubMed  CAS  Google Scholar 

  32. Koh KK, Oh PC, Quon MJ. Does reversal of oxidative stress and inflammation provide vascular protection? Cardiovasc Res. 2009;81:649–59.

    Article  PubMed  CAS  Google Scholar 

  33. Gori T, Münzel T. Oxidative stress and endothelial dysfunction: therapeutic implications. Ann Med. 2011;43:259–72.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Cardiology and Nephrology, Dokkyo Medical University, Mibu, Tochigi, 321-0293, Japan

    Toshihiko Ishimitsu, Eri Ohno, Yasuhiko Ueno, Shou Onoda, Akihiko Nagase, Takehiro Ohira, Nobuyuki Nakano & Hiroshi Satonaka

Authors
  1. Toshihiko Ishimitsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eri Ohno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasuhiko Ueno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shou Onoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akihiko Nagase
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takehiro Ohira
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nobuyuki Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiroshi Satonaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshihiko Ishimitsu.

About this article

Cite this article

Ishimitsu, T., Ohno, E., Ueno, Y. et al. Effects of atorvastatin and ezetimibe on endothelial function in dyslipidemic patients with chronic kidney disease. Clin Exp Nephrol 18, 704–710 (2014). https://doi.org/10.1007/s10157-013-0904-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-013-0904-7

Keywords

Search

Navigation